Medical Roundup #7
Regulators rejected Moderna's application despite previously approving the trial design, sparking a political firestorm.
In a major regulatory reversal, the FDA has refused to accept Moderna's application for its first mRNA seasonal flu vaccine, despite the company having previously received agency feedback that its $750 million study design was acceptable. The FDA's February 3rd letter stated the application lacked an 'adequate and well-controlled' trial because the control arm didn't reflect the current U.S. standard of care, though it identified no specific safety or efficacy concerns. Moderna has called the refusal inconsistent and requested a meeting to understand the path forward.
The decision has sparked intense criticism from medical innovation advocates, including economist Alex Tabarrok, who framed it as 'the FDA is FDAing Again.' Critics argue the move represents a shift toward excessive paternalism under new leadership, with a particular bias against mRNA vaccines. The controversy is compounded by the recent dismissal of Jim O'Neill, a key advocate for regulatory reform, from the Trump administration. The incident highlights the high-stakes tension between rigorous safety oversight and the need to accelerate access to breakthrough medical technologies.
- FDA rejected Moderna's flu vaccine application after previously approving its $750M trial design, citing control arm issues.
- The decision has ignited a political debate, with critics like Alex Tabarrok calling it paternalistic and anti-innovation.
- The controversy follows the dismissal of reform advocate Jim O'Neill, signaling a potential shift in FDA policy direction.
Why It Matters
This case sets a critical precedent for how regulators will evaluate future mRNA therapies and impacts billions in biotech investment.